Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:22:08.321Z.
Calculation as of: 2026-10-06T18:22:08.321Z.
Quote observation: 2026-10-06T18:19:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9bf447c1d5373d17b51517f64cfe8ce44e33b4ae98b3907fdc05662a19d62e0e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Metagenomi, Inc. Common Stock
Market Cap
$39.06M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.81M
EV/EBIT Ratio
74.50x
TTM Avg
60.42x
3Y Avg
123.40x
5Y Avg
130.57x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $39.06M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.81M | 74.50x | 60.42x | 123.40x | 130.57x |
| Nephros, Inc. (NEPH)vs › | $37.89M | 20.75x | 36.10x | 319.62x | 319.62x |
| Incannex Healthcare Limited (IXHL)vs › | $37.94M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.54M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.70M | N/A | N/A | N/A | N/A |
| Veru Inc. (VERU)vs › | $41.30M | N/A | 709.67x | 709.67x | 707.26x |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.51M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | N/A | N/A | N/A | N/A |
| Precipio, Inc. (PRPO)vs › | $42.15M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
